Lv2
190 积分 2024-02-17 加入
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2个月前
已关闭
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2个月前
已完结
Re: Thomas Powles, Begoña Pérez-Valderrama, Shilpa Gupta, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024;390:875–88
2个月前
已关闭
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2个月前
已完结
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial
3个月前
已关闭
Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy
3个月前
已完结
Hepatectomy alters adjuvant anti-PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy
5个月前
已完结
Step-by-Step Approach to Intracorporeal Urinary Diversion, Ileal Conduit, and W-Neobladder: The Roswell Park Technique
6个月前
已完结
Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
7个月前
已完结
Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
7个月前
已完结
皖公网安备34019202002308
